Literature DB >> 12411291

Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation.

Ton Lisman1, Sultana Moschatsis, Jelle Adelmeijer, H Karel Nieuwenhuis, Philip G De Groot.   

Abstract

A novel approach to treat bleeding episodes in patients with Glanzmann thrombasthenia (GT) and perhaps also in patients receiving alpha IIb beta 3 inhibitors is the administration of recombinant factor VIIa (rFVIIa). The mechanism of action of rFVIIa in these patients is, however, still unclear. We studied the effect of rFVIIa-mediated thrombin formation on adhesion of alpha IIb beta 3-deficient platelets under flow conditions. Adhesion of alpha IIb beta 3-deficient platelets to the extracellular matrix (ECM) of stimulated human umbilical vein endothelial cells or to collagen type III was studied using a model system with washed platelets and red cells. When alpha IIb beta 3-deficient platelets were perfused over the surface at arterial shear rate for 5 minutes, a low surface coverage was observed (GT platelets, mean +/- SEM, 37.5% +/- 5.0%; normal platelets preincubated with an RGD-containing peptide, 7.4% +/- 2.1%). When rFVIIa, together with factors X and II, was added to the perfusate, platelet deposition significantly increased (GT platelets, mean +/- SEM, 67.0% +/- 4.3%; normal platelets preincubated with an RGD-containing peptide, 48.2% +/- 2.9%). The same effect was observed when normal platelets were pretreated with the commercially available anti-alpha IIb beta 3 drugs abciximab, eptifibatide, or tirofiban. It was shown that tissue factor-independent thrombin generation (presumably induced by binding of rFVIIa to adhered platelets) was responsible for the increase in platelet deposition. In conclusion, defective adhesion of alpha IIb beta 3-deficient platelets to ECM can be restored by tissue factor-independent rFVIIa-mediated thrombin formation. The enhanced generation of platelet procoagulant surface facilitates fibrin formation, so that lack of platelet aggregate formation might be compensated for.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411291     DOI: 10.1182/blood-2002-09-2761

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms.

Authors:  Shiva Keshava; Usha R Pendurthi; Charles T Esmon; L Vijaya Mohan Rao
Journal:  J Thromb Haemost       Date:  2020-06-25       Impact factor: 5.824

2.  Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation.

Authors:  Jack D Stopa; Donna Neuberg; Maneka Puligandla; Bruce Furie; Robert Flaumenhaft; Jeffrey I Zwicker
Journal:  JCI Insight       Date:  2017-01-12

Review 3.  Flow chamber and microfluidic approaches for measuring thrombus formation in genetic bleeding disorders.

Authors:  Rogier M Schoeman; Marcus Lehmann; Keith B Neeves
Journal:  Platelets       Date:  2017-05-22       Impact factor: 3.862

Review 4.  Proteases as therapeutics.

Authors:  Charles S Craik; Michael J Page; Edwin L Madison
Journal:  Biochem J       Date:  2011-04-01       Impact factor: 3.857

5.  Surgical treatment of cecal cancer in a patient with Glanzmann's thrombasthenia: report of a case.

Authors:  Akira Kabashima; Naoyuki Ueda; Yusuke Yonemura; Kojiro Mashino; Kyuzo Fujii; Tetsuo Ikeda; Hideya Tashiro; Hisanobu Sakata
Journal:  Surg Today       Date:  2009-11-01       Impact factor: 2.549

Review 6.  Glanzmann thrombasthenia.

Authors:  Alan T Nurden
Journal:  Orphanet J Rare Dis       Date:  2006-04-06       Impact factor: 4.123

Review 7.  Glanzmann Thrombasthenia: Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies.

Authors:  Natalie Mathews; Georges-Etienne Rivard; Arnaud Bonnefoy
Journal:  J Blood Med       Date:  2021-06-11

Review 8.  Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.

Authors:  Man-Chiu Poon
Journal:  Vasc Health Risk Manag       Date:  2007
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.